A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.

@article{Langman2016ADP,
  title={A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.},
  author={Craig B Langman and Danica Grujic and Rita M Pease and Linda H. Easter and Jennifer Nezzer and Alexey L. Margolin and Lee R. Brettman},
  journal={American journal of nephrology},
  year={2016},
  volume={44 2},
  pages={
          150-8
        }
}
BACKGROUND Hyperoxaluria may result from increased endogenous production or overabsorption of dietary oxalate in the gastrointestinal tract leading to nephrolithiasis and, in some, to oxalate nephropathy and chronic kidney disease. ALLN-177 is an oral formulation of a recombinant, oxalate specific, microbial enzyme oxalate decarboxylase intended to treat secondary hyperoxaluria by degrading dietary oxalate in the gastrointestinal tract, thereby reducing its absorption and subsequent excretion… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Recurrence of hy - peroxaluria and kidney disease after combined intestine - kidney transplantation for enteric hyperoxaluria

  • H Xu, AL Zisman, FL Coe, EM Worcester
  • Am J Nephrol
  • 2016

Medical management of kidney stones: AUA guideline

  • M Monga, KL Penniston, GM Preminger, TM Turk, JR White
  • J Urol
  • 2014

Similar Papers

Loading similar papers…